TY - JOUR
T1 - Deep and future insights into neuromodulation therapies for heart failure
AU - Kishi, Takuya
N1 - Funding Information:
Grant-in-Aid for Scientific Research (C) (no. 24591058 to Dr Kishi) and a Grant-in Aid for Young Scientists (B) (no. 22790709 to Dr Kishi) from the Ministry of Education, Culture, Sports, Science to Dr Kishi.
Publisher Copyright:
© 2016 Japanese College of Cardiology
PY - 2016/11/1
Y1 - 2016/11/1
N2 - Major pathophysiology of heart failure is an autonomic nervous system dysfunction as a result of excess sympathoexcitation and/or withdrawal of vagal nerve activity. Although we already have various pharmacological and non-pharmacological therapies for heart failure, survival of heart failure patients remains around 50%. To achieve further reductions in morbidity and mortality of heart failure, neuromodulations with devices, such as baroreflex activating therapy, vagal nerve stimulation, renal sympathetic denervation, spinal cord stimulation, and left cardiac sympathetic denervation, have been expected. Although all of these neuromodulations have benefits on heart failure, efficacy, and safety in preclinical and small-sized clinical studies, the benefits on heart failure have been insufficient and controversial compared to our expectations in large-sized randomized trials. However, we should develop and apply these novel therapies for the patients with heart failure in the near future.
AB - Major pathophysiology of heart failure is an autonomic nervous system dysfunction as a result of excess sympathoexcitation and/or withdrawal of vagal nerve activity. Although we already have various pharmacological and non-pharmacological therapies for heart failure, survival of heart failure patients remains around 50%. To achieve further reductions in morbidity and mortality of heart failure, neuromodulations with devices, such as baroreflex activating therapy, vagal nerve stimulation, renal sympathetic denervation, spinal cord stimulation, and left cardiac sympathetic denervation, have been expected. Although all of these neuromodulations have benefits on heart failure, efficacy, and safety in preclinical and small-sized clinical studies, the benefits on heart failure have been insufficient and controversial compared to our expectations in large-sized randomized trials. However, we should develop and apply these novel therapies for the patients with heart failure in the near future.
UR - http://www.scopus.com/inward/record.url?scp=84995388347&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84995388347&partnerID=8YFLogxK
U2 - 10.1016/j.jjcc.2016.05.010
DO - 10.1016/j.jjcc.2016.05.010
M3 - Review article
C2 - 27293020
AN - SCOPUS:84995388347
VL - 68
SP - 368
EP - 372
JO - Journal of Cardiology
JF - Journal of Cardiology
SN - 0914-5087
IS - 5
ER -